Neoadjuvant immune checkpoint therapy trialled for NSCLC

Two different phase 2 trials suggest most patients can go on to have full resection

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

illustration of lungs

Two phase 2 trials of preoperative immune checkpoint therapy have shown that it does not compromise surgery in patients with early non-small cell lung cancer (NSCLC).

Results of the two French trials — IONESCO and PRINCEPS — were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.

In IONESCO, 46 patients with early stage